In Tanzania & Bangladesh, biosimilar insulin glargine can be cost-effective vs NPH for youth w/T1D—but it hinges on price & delivery device. Cartridges worked in Bangladesh; vials could work in both if💲right. Fewer nighttime hypoglycemia events drive the benefit. journals.plos.org/plosone/arti...

Study of VA data found 67% of outpatient drug supply disruptions led to shortages. Orders spiked sharply before shortages while fills dropped—suggesting ordering surges may be an early warning sign of impending drug shortages. www.sciencedirect.com/science/arti...

CP3's Dr. Katie Suda & @pharmacy.utoronto.ca @mina-t.bsky.social recently shared their drug shortages work to the 10th Annual PITT OHIO 2026 Supply Chain Management Symposium, in a presentation titled "The Pharmaceutical Supply Chain in the Real World: From Data to Policy Solutions."

CP3's @timandersonmd.bsky.social contributed to the new @americanheart.bsky.social guidelines to address evaluation, management, & monitoring of individuals with dyslipidemias. Read the guidelines here: www.ahajournals.org/doi/10.1161/...

Pharmacy owners/managers, pharmacists, & techs: Share how Medicare Part D changes under the IRA are affecting your pharmacy & patients. Participate a 60-min virtual interview ($100 honorarium) with researchers from RAND/Vanderbilt/CP3. Details below. Sign up: answer.rand.org/IRA

The Incidental Economist explores how to pay for high-cost #genetherapies, including “rev pay” models that spread costs over time to address large upfront prices, payer risk, & patient mobility. The piece cites CP3 research on financing for gene therapies. theincidentaleconomist.com/wordpress/ge...

New @jamainternalmed.com study led by CP3’s @timandersonmd.bsky.social: a virtual, team-based program (pharmacist tapering + mindfulness CBT) helped older adults reduce benzodiazepines by ~60%. Feasible, acceptable, and ready for multi-site testing. link.springer.com/article/10.1...

Dental visits jump after starting medications for opioid use disorder (MOUD)—across methadone, buprenorphine, and naltrexone. Likely reflects increased health-seeking, not drug harm. Studies on dental risks should account for this behavior shift. journals.lww.com/journaladdic...

Join us May 12 at noon for a seminar from CP3/Pitt Pharmacy Visiting Scholar Adam Bress. All are welcome! Register: calendar.pitt.edu/event/semina...

@jamainternalmed.com editorial highlights early impact of 2024 IRA Part D reforms: cost-related💊nonadherence fell among Medicare beneficiaries but rose among commercially insured adults. Gains are promising, but affordability challenges remain. jamanetwork.com/journals/jam...

🆕@statnews.com article highlights shifts in CVD prevention guidelines, including considering statins as early as age 30 & using updated risk tools. CP3’s @timandersonmd.bsky.social notes focus on balancing long-term benefits w/risks & IDing high-risk pts earlier. www.statnews.com/2026/03/13/h...

🆕study of Medicare beneficiaries w/incident osteoarthritis found hypertension didn't influence initial analgesic choice. Intra-articular injections & oral NSAIDs most common; topical NSAID use⬆️, opioid combos⬇️. Co-authored by CP3’s @jennylociganic.bsky.social. pubmed.ncbi.nlm.nih.gov/41833532/

🆕paper introduces DF-learner, a distributed learning approach to estimate heterogeneous tx effects across multiple data sites w/o sharing individual-level data. Applied to MOUD using PA Medicaid data, it enables privacy-preserving, efficient multi-site analysis. academic.oup.com/biometrics/a...

🆕study in @plosone.org finds many US medical school conflict-of-interest policies remain less stringent than expert recommendations, highlighting need for stronger policies & enforcement to protect medical education. Co-authored by CP3’s @timandersonmd.bsky.social. journals.plos.org/plosone/arti...

🆕research with CP3 collaborators develops an ML model using EHR data to predict 3-month risk of opioid use disorder after opioid initiation. The model showed strong performance and could help health systems identify high-risk patients earlier and target prevention. www.jmir.org/2026/1/e79482/

People with neurogenic bladder may experience substantial QoL impacts from UTIs, & patient-centered interventions may be needed to decrease the impact of UTIs. Co-authored by CP3's Dr. Katie Suda. Read more: onlinelibrary.wiley.com/doi/10.1002/...

🆕study with CP3’s @walidgellad.bsky.social & Noah Feder, finds MS drug list prices keep climbing, but net prices diverge. Analysis began when lead author Dr. Dan Hartung was CP3 visiting scholar. Read more: www.neurology.org/doi/10.1212/...

🆕editorial in @jamainternalmed.com by CP3’s @timandersonmd.bsky.social & colleagues examines when statins should be used for prevention of ASCVD. As risk calculators evolve, debate continues over lowering treatment thresholds. jamanetwork.com/journals/jam...

In @jamainternalmed.com, CP3's @timandersonmd.bsky.social & coauthors describe strategies for medication safety for older adults in the emergency department. jamanetwork.com/journals/jam...

New @cidrap.bsky.social article offers tips to avoid inappropriate dental antibiotic use to curb resistance and patient harm. CP3’s Katie Suda was interviewed, highlighting stewardship strategies for dentists to choose when antibiotics are truly needed. www.cidrap.umn.edu/antimicrobia...

New @cidrap.bsky.social article shows dentists still write millions of antibiotic prescriptions annually, many of which may be unnecessary. CP3’s Dr. Katie Suda was consulted on the need for improved stewardship in dental settings to curb overuse and resistance. www.cidrap.umn.edu/antimicrobia...

🆕study co-authored by CP3’s @timandersonmd.bsky.social finds 9% of US adults 30–59 have ⬆️30-year ASCVD risk despite⬇️10-year risk. Many have uncontrolled risk factors, & expanding statins could benefit ~2.5M more adults. Long-term risk may reshape prevention. pmc.ncbi.nlm.nih.gov/articles/PMC...

🆕study led by CP3’s @bryantshuey.bsky.social finds employer-mandated switches to high-deductible plans were linked to delays in OUD-related high-acuity care and 37% fewer high-acuity care days, raising concerns about cost-sharing barriers to timely treatment. journals.lww.com/journaladdic...

The agenda for @cpddorg.bsky.social #cpdd26 is out, and we can't wait to join our colleagues from @brownpublichealth.bsky.social to share lessons learned from implementing #machinelearning driven #overdose prevention interventions! cpdd.societyconference.com/conf/#sessio...

New @plosone.org study finds long-term opioid therapy is linked to higher risk of infection-related dental outcomes in a national VA cohort, underscoring oral health risks in chronic opioid users. CP3's Dr. Katie Suda is a co-author. journals.plos.org/plosone/arti...

CP3's @timandersonmd.bsky.social spoke with @statnews.com about the importance of conversations between patient and prescriber when making decisions about statins and other medications. Read more: www.statnews.com/2026/02/05/s...

🆕paper co-authored by CP3’s @timandersonmd.bsky.social highlights how longer life expectancy has expanded the number of older adults with CVD risk. Using the Geriatric 5Ms, it reviews new BP & lipid guidelines to support personalized prevention in aging adults. www.sciencedirect.com/science/arti...

ICYMI: CP3's Dr. Tom Radomski reflects on moving from student to associate director of Pitt's ICRE in Pitt Med magazine. (Bonus cameos of CP3 Director @walidgellad.bsky.social & faculty affiliate Dr. Julie Donohue!) www.pittmed.pitt.edu/news/institu...

Our latest newsletter is live! Through the holiday break and a huge winter storm, we kept busy! createsend.com/t/j-DBA41D16...

🆕study by CP3’s @timandersonmd.bsky.social shows that even when discharge summaries and instructions align, older adults misunderstood >50% of cardiometabolic 💊 changes. Concordance doubled understanding but clearer discharge communication needed. agsjournals.onlinelibrary.wiley.com/doi/10.1111/...

CP3 Director @walidgellad.bsky.social will moderate a panel at the Novel Solutions to Address the Rising Cost of Oncology Drugs conference, hosted by the University of Chicago & Georgetown Law, focused on demand-side strategies to improve cancer drug affordability. cpt.uchicago.edu/program/

🆕 Study co-authored by CP3’s @jennylociganic.bsky.social used EHR data to build #machinelearning models predicting which patients receive pharmacogenetic testing for #opioid therapy. Results show strong performance and promise for precision pain care. medinform.jmir.org/2026/1/e81048

🆕study co-authored by CP3’s @walidgellad.bsky.social & Noah Feder finds only ~30% of hospitals fully comply with CMS price transparency rules, with most failing to report negotiated rates. PPS-exempt hospitals showed similar gaps. www.sciencedirect.com/science/arti...

New @arstechnica.com piece highlights work by CP3’s @timandersonmd.bsky.social showing that #GLP-1 drugs improve heart health, but benefits fade when treatment stops—raising important questions about long-term use, adherence, and chronic disease management. arstechnica.com/health/2025/...

🆕study co-authored by CP3’s @timandersonmd.bsky.social finds current transitions of care programs are fragmented, harming pt handoffs. Improving outcomes will require addressing social needs, stronger leadership support, & pt-centered care. shmpublications.onlinelibrary.wiley.com/doi/10.1002/...

New study co-authored by CP3’s Dr. Ted Park finds postoperative opioid and benzodiazepine prescribing often mirrors patients’ pre-surgery use rather than new surgical needs. Understanding these patterns is key to tailoring surgery-specific interventions. journals.lww.com/journalacs/a...

Our team worked with partners at ACDHS to develop a risk prediction model to determine risk of overdose after a person leaves jail. Time spent in a carceral setting has a huge impact on people's vulnerability. cp3.pitt.edu/allegheny-co...

We love seeing CP3's Dr. Sarah Belcher & Dr. Luke Berenbrok's work highlighted in Pitt Research's Annual Report! We continue to make impact on healthcare! Dr. Belcher: www.research.pitt.edu/report/impro... Dr. Berenbrok: www.research.pitt.edu/report/impro...

We're so happy that @drjuanhc.com is officially part of Pitt and CP3! Our work together will be even stronger with you here, Juan!

Excited to start the year by planning to share our #riskprediction work at 2 conferences: @upmc.com Digital Health Summit & @cpddorg.bsky.social #cpdd36! At #cpdd26, we'll join colleagues from @brownpublichealth.bsky.social to share lessons learned from our experience doing this work. See you there!

New study co-authored by CP3’s Dr. Julie Donohue highlights Medicaid’s crucial role in covering seriously ill adults and shows the need for Medicaid programs to focus more on ICU patients before, during, and after hospitalization to improve care and outcomes. pmc.ncbi.nlm.nih.gov/articles/PMC...

New national study shows alcohol-related hospitalizations stayed stable from 2016–2022, but mortality, length of stay, & costs rose. Findings highlight the need for prevention & earlier AUD treatment to improve outcomes & reduce spending. @timandersonmd.bsky.social jamanetwork.com/journals/jam...

Many older adults are stopping their #GLP-1 medications. @nytimes.com spoke with experts, including CP3's @timandersonmd.bsky.social to learn more. @pittdeptofmed.bsky.social @pittgim.bsky.social www.nytimes.com/2025/12/21/h...

More than 1 in 10 older adults in Medicare Part D Medication Therapy Management use multiple CNS meds, increasing fall risk, yet only ~1/3 get a comprehensive med review. Better engagement needed to reduce risk. @timandersonmd.bsky.social www.jmcp.org/doi/10.18553...

Congrats to Yujin Seo (CMU), working with CP3’s Dr. Katie Suda, on presenting at the IQVIA Institute Research Forum. Her poster shows drug shortages hit older adults hardest, with faster fill declines among Medicare/Medicaid patients and those linked to rural or lower-income prescribers.

New study co-authored by CP3’s @timandersonmd.bsky.social shows limited lecanemab uptake in the VHA and that nearly 30% of patients had ARIA or stroke within 7 months of starting treatment, highlighting the need for careful long-term safety and effectiveness monitoring. www.mdpi.com/2077-0383/14...

Welcome to CP3! Juan M. Hincapie-Castillo (@drjuanhc.com) will join Pitt’s School of Pharmacy as Associate Professor (pending) in Jan 2026 & as a CP3 faculty affiliate. A longtime collaborator & 2024 Pharmacoequity panelist, his work focuses on legal epidemiology & evidence-based policymaking.

🆕study in @addictionjournal.bsky.social shows how lookback window & washout choices in MOUD research affect sample size, demographics, & tx start misclassification. It offers practical guidance to improve comparative studies in #opioid use disorder research. onlinelibrary.wiley.com/doi/10.1111/...

CP3 Associate Director Dr. Katie Suda was interviewed for Dr. Bicuspid on the risks of prescribing #opioids to pediatric patients. Read the interview and more on Dr. Suda's study here: www.drbicuspid.com/dental-speci...

New study finds telehealth and a gradual return to in-person visits helped restore outpatient care for patients with atrial fibrillation after the pandemic. But recovery was uneven, with notable differences by patients’ pre-pandemic outpatient use. link.springer.com/article/10.1...